Solutions for Healthy Communities (SHC) Global Grants Program is sponsored by MSD (Merck Sharp & Dohme). MSD's Solutions for Healthy Communities is a global grants program investing in innovative solutions to advance equitable access to health.

Solutions for Healthy Communities - MSD Solutions for Healthy Communities Solutions for Healthy Communities (SHC) is our global grants program focused on investing in innovative solutions to advance equitable access to health around the world. Jump to applications FAQs.

SHC: grounded in the power of communities Our company has set a public commitment to advance access to health for people in low- and middle-income countries and for underserved populations in high-income countries. As part of that commitment, SHC launched in 2023. The program aims to catalyze innovation in locally led solutions that facilitate access to health care for underserved populations in areas where our company has a presence.

SHC was developed based on the belief that local organizations know their communities best, and are best positioned to create meaningful, lasting change in the regions where they work.

How SHC drives access to health Empowering people and communities with health knowledge Designing and testing models of care that better meet the needs of underserved populations Strengthening and expanding the community healthcare workforce Building capacity of community health organizations Strengthening regional and national health systems We select grantee organizations that leverage local knowledge and skills to advance access to health.

They are serving those living in poverty, in underrepresented ethnic groups, who have diverse gender identities and/or sexual orientations, or who are displaced by humanitarian crises or conflicts. Learn more in our FAQs below. Of the 385 applicants, 36 projects representing 24 countries were selected from around the world; they collectively received $7 million over two years to advance their proposals.

Projects in our inaugural cohort spanned multiple therapeutic areas, including oncology, diabetes, cardiovascular disease, sexual and reproductive health, and maternal and child health. Learn more in our FAQs below.

Beebe Medical Center Inc. d/b/a Beebe Healthcare Blue Ridge Free Clinic, Inc. Business for Health Solutions, International, Inc. Comie En Union para Salvadorenos (CEUS) Foundation Center for Health Policies and Services Foundation for Health Leadership & Innovation Fundación Mexicana Para la Salud, A. C.

Health Promotion Council of Southeastern Pennsylvania, Inc. HMH Hospitals Corporation Kilkenny Cancer Support Centre Ltd The King Hussein Cancer Foundation Massachusetts General Hospital National Aboriginal Community Controlled Health Organisation Robert Wood Johnson University Hospital at Rahway Shel Bar – The Sarit Levy and Bracha Rosenberg z”l organization for Women’s Cancer (RA) United Nations Population Fund (UNFPA) in Serbia University of Nebraska Foundation Valley Youth House Committee, Inc. Vishwanath Cancer Care Foundation Yayasan Jalin Komunikasi Indonesia (Jalin Foundation) Frequently asked questions What are the characteristics of a successful grant applicant?

Grant applicants must be consistent with the following: They seek to expand health care access via community-led solutions that reach historically underserved populations. They implement innovative solutions in their community to improve the reach and impact of health services. Those solutions should drive impact across therapeutic areas, including, but not limited to, oncology, vaccines, infectious disease or diabetes.

The SHC team recognizes that organizations know the health needs of their community best and as such will evaluate grant proposals based on the information communicated in the proposal. Who is eligible to apply for an SHC grant? Eligible applicants are nonprofit organizations within 50 miles of an MSD site and have program objectives that align with SHC’s goal to advance access to health care for historically underserved populations.

How can my organization apply? Applications for the 2026-2027 SHC cohort open January 13, 2025, and close February 28, 2025. How are applications evaluated?

Proposals are evaluated based on criteria, including, but not limited to, clarity of objectives and outcomes, demonstrated understanding of locally relevant barriers and opportunities to advance access to health care for specific underserved population groups, demonstrated capacity and capabilities to carry out proposed activities, anticipated reach and opportunities to leverage, scale and sustain efforts beyond this grant.

What is the term length of the grant? Contracts will be fully executed no later than December 2025. Program implementation is expected to begin January 2026 and be completed by December 2027.

This is a two-year funding commitment. Forward-Looking Statement of Merck & Co. , Inc., Rahway, N.

J. , USA This website of Merck & Co. , Inc., Rahway, N.

J. , USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties.

There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2025 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site ( www. sec. gov ).

The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.